New antibody drug may boost transplant success in tough lymphoma
NCT ID NCT07387848
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests glofitamab, an antibody that helps immune cells attack lymphoma, in 40 adults with relapsed or refractory diffuse large B-cell lymphoma who are eligible for a stem cell transplant. Glofitamab is given before transplant as a 'bridge' to shrink the cancer, and again after transplant to prevent relapse. The study aims to see if this approach improves how long patients stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glofitamab
What this could lead to
If successful, glofitamab could improve the chance of keeping lymphoma in remission after a stem cell transplant, offering a new option for patients who cannot access CAR-T therapy.
What could go wrong
This is a small, early-phase study with only 40 people, so results may not apply to everyone. Glofitamab can cause immune-related side effects, and it is not yet proven to be better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••